Xcout Intel
Initiator Pharma
Initiator Pharma is a clinical-stage biotechnology company that develops therapeutics targeting monoamine neurotransmitters for conditions such as erectile dysfunction, vulvodynia, and female sexual dysfunction. The company advances a pipeline of clinical and preclinical drug candidates, including its lead asset pudafensine, to address unmet medical needs in sexual medicine.
Subscribe to see Initiator Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Initiator Pharma at a glance
Initiator Pharma is a health care company headquartered in Denmark. Xcout tracks 6 named people at Initiator Pharma, including Claus Elsborg Olesen (CEO and board member).
Initiator Pharma leadership
- Claus Elsborg OlesenCEO and board member
- Magnus PerssonChairman of the Board
- Annette ColinBoard member
- Christina LloydBoard member
- Gunilla EkströmBoard member
- Peter HolmBoard member
Initiator Pharma competitors
A few of Initiator Pharma's closest competitors — see the full list of competitors and alternatives →
Gabather is a pharmaceutical company that develops therapeutics for neuropsychiatric disorders, focusing on treatments for conditions such as anxiety, depression, psychosis, pain, and Alzheimer’s disease. The company utilizes proprietary drug candidates targeting the GABAA receptor system to restore brain balance and enhance cognitive function.
Equator Therapeutics is a privately held biotechnology company headquartered in San Francisco, California. The company leverages recent scientific breakthroughs to enable the pharmacological stimulation of thermogenesis for achieving sustained weight loss.
FemmePharma Consumer Healthcare develops and sells health and wellness products designed for women experiencing perimenopause and menopause. Their product lineup includes personal lubricants, moisturizers, and dietary supplements that target symptoms such as vaginal dryness, hot flashes, and sleep disturbances.
Enorama Pharma is a Swedish pharmaceutical company that develops and commercializes consumer-friendly oral nicotine products, specifically focusing on tobacco-free white snus. The company markets its products under its proprietary NIC-S brand and through private labels, with a primary focus on the U.S. market.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for central nervous system disorders. Its pipeline focuses on treating conditions such as suicidal depression, suicidal bipolar depression, and post-traumatic stress disorder. The company utilizes a proprietary NMDA platform for its therapeutic developments.
Klaria Pharma Holding is a pharmaceutical development company that utilizes a proprietary alginate film technology to deliver medications directly through the oral mucosa into the bloodstream. The company focuses on developing alternative delivery methods for drugs traditionally administered via injections, targeting therapeutic areas such as migraine, acute allergic reactions, and organ transplantation.
Get Initiator Pharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Initiator Pharma? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Initiator Pharma in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access